This article is more than 5 years old. Information may no longer be current.
Xen 45 gel stent with MMC may be combined with cataract surgery
Click Here to Manage Email Alerts
SAN DIEGO — The Xen 45 gel stent implant with mitomycin C may be used safely in conjunction with cataract surgery, according to a presentation here.
At the American Society of Cataract and Refractive Surgery annual meeting, Arsham Sheybani, MD, and colleagues presented 1-year results of the prospective, nonrandomized, multicenter clinical trial of open angle glaucoma patients with IOP ranging from 18 mm Hg to 35 mm Hg who underwent cataract surgery and implantation of the Xen 45 gel stent (AqueSys).
Arsham Sheybani
The Xen 45 implant is a 6 mm long gelatin stent with a 45 µm inner lumen gel stent that is cross-linked with glutaraldehyde that connects the anterior chamber to the subconjunctival space, Sheybani said.
Preoperatively, 0.14 mL of mitomycin C was injected subconjunctivally before the gel stent was injected ab interno.
Preoperatively, mean IOP was 21.4 mm Hg and mean number of medications per patient was 2.3. At 12 months, mean IOP decreased to 13.1 mm Hg, and mean number of medications was reduced to 0.9.
One patient required additional glaucoma surgery, one patient required device explant, three patients had hypotony that resolved by week 1 postoperatively, and the needling rate was 10.4%.
“The [XEN] bleb is very different than what you are used to with the trabeculectomy bleb,” Sheybani said. “This really is a pretty safe and efficacious procedure to combine with cataract surgery.” – by Kristie L. Kahl
Disclosure: Sheybani reports he is a researcher for AqueSys Inc.